SEARCH

SEARCH BY CITATION

References

  • 1
    Allen, T.M. (1998) Oncologic agents in sterically stabilized liposomes: basic considerations. Long Circulating Liposomes: Old Drugs, New Therapeutics (ed. by M. C. Woodle and G. Storm), pp. 19 28. Springer-Verlag and Landes Bioscience.
  • 2
    Anderlini, P., Benjamin, R.S., Wong, F.C., Kantarjian, H.M., Andreeff, M., Kornblau, S.M., O'Brian, S., Mackay, B., Ewer, M.S., Pierce, S.A., Estey, E.H. (1995) Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukaemia and myelodysplasia. Journal of Clinical Oncology, 13, 2827 2834.
  • 3
    Arcamone, F. (1987) Clinically useful doxorubicin analogues. Cancer Treatment Reviews, 14, 159 161.
  • 4
    Basser, R.L. & Green, M.D. (1993) Complications of treatment: strategies for prevention of anthracycline cardiotoxicity. Cancer Treatment Reviews, 19, 57 77.
  • 5
    Bielack, S.S., Erttmann, R., Kempf-Bielack, B., Winkler, K. (1996) Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid nineties? European Journal of Cancer, 32A, 1652 1660.
  • 6
    Billingham, M.E., Mason, G.W., Bristow, M.R., Daniels, J.R. (1978) Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treatment Reports, 62, 865 872.
  • 7
    Bonadonna, G., Zambetti, M., Valagussa, P. (1996) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. Journal of the American Medical Association, 273, 542 547.
  • 8
    Boucek, R.J., Olsen, R.D., Brenner, D.E., Ogunbumni, E.M., Inui, M., Fleischer, S. (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. Journal of Biological Chemistry, 262, 15851 15856.
  • 9
    Boucek, R.J. (1998) Mechanism for anthracycline-induced cardiomyopathy: clinical and laboratory correlations. Progress in Pediatric Cardiology, 8, 59 70.
  • 10
    Breed, J.G., Zimmerman, A.N., Dormans, J.A., Pinedo, H.M. (1980) Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Research, 40, 2033 2038.
  • 11
    Bristow, M.R., Mason, J.W., Billingham, M.E., Daniel, J.R. (1981) Dose–effect relationship in doxorubicin cardiomyopathy. American Heart Journal, 102, 709 718.
  • 12
    Bukowski, R. (1999) Cytoprotection in the treatment of pediatric cancer: review of current stategies in adults and their application to children. Medical and Pediatric Oncology, 31, 124 134.
  • 13
    Bu'Lock, F.A., Gabriel, H.M., Oakhill, A., Mott, M.G., Martin, R.P. (1993) Cardioprotection by ICRF-187 against high-dose anthracycline toxicity in children with malignant disease. British Heart Journal, 70, 185 8.
  • 14
    Cameron, E.H., Lipshultz, S.E., Tarbell, N.J., Mauch, P.M. (1998) Cardiovasculat disease in long-term survivors of pediatric Hodgkin's disease. Progress in Pediatric Cardiology, 8, 139 144.
  • 15
    Casper, E.S., Gaynor, J.J., Hajdu, S.I., Magill, G.B., Tan, C., Friedrich, C., Brennan, M.F. (1991) A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer, 68, 1221 1229.
  • 16
    Chevilland, S., Vielh, P., Bastian, G., Coppey, J. (1992) A single 24h contact time with adriamycin provokes the emergence of resistant cells expressing the Gp 170 protein. Anticancer Research, 12, 495 500.
  • 17
    Creighton, A.M., Hellman, K., Whitecross, S. (1969) Antitumor activity in a series of biodiketopiperazines. Nature, 222, 384 385.
  • 18
    Cusack, B.J., Young, S.P., Driskell, J., Olson, R.D. (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusions of doxorubicin in the rabbit. Cancer Chemotherapy and Pharmocology, 32, 53 55.
  • 19
    Davies, K.J.A. & Doroshow, J.H. (1985) Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracyclines radical formation by NADH dehydrogenase. Journal of Biological Chemistry, 261, 3060 3067.
  • 20
    De Valeriola, D. (1994) Dose optimization of anthracyclines. Anticancer Research, 14, 2307 2314.
  • 21
    Doroshow, J.H. & Davies, K.J.A. (1985) Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide and hydroxl radical. Journal of Biochemical Chemistry, 261, 3068 3074.
  • 22
    Dorr, R.T. (1996) Cytoprotective agents for anthracyclines. Seminars in Oncology, 23, 23 24.
  • 23
    Ewer, M.S., Ali, K.M., Mackey, B., Wallace, S., Valdivieso, M., Legha, S.S., Benjamin, R.S., Haynie, T.P. (1984) A comparison of cardiac biopsy and ejection fraction estimations in patients receiving adriamycin. Journal of Clinical Oncology, 2, 112 117.
  • 24
    Ewer, M.S., Jaffe, N., Reid, H., Zietz, H.A., Benjamin, R.S. (1998). Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Medical and Pediatric Oncology, 31, 512 515.
  • 25
    Forssen, E.A. & Proffitt, R.T. (1998) Design and development of long circulating liposomal daunorubicin for in vivo targetting of solid tumours: DaunoXome. Long Circulating Liposomes: Old Drugs, New Therapeutics (ed. by M. C. Woodle and G. Storm), pp. 72 96. Springer-Verlag and Landes Bioscience.
  • 26
    Gabizon, A.A. (1994) Liposomal anthracyclines. Hematology/Oncology Clinics of North America, 8, 431 450.
  • 27
    Gabizon, A.A. & Muggia, F.M. (1998) Initial clinical evaluation of Pegylated-liposomal doxorubicin in solid tumours. Long Circulating Liposomes: Old Drugs, New Therapeutics (ed. by M. C. Woodle and G. Storm), pp. 165 174. Springer-Verlag and Landes Bioscience.
  • 28
    Gill, P.S., Espina, B.M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J.A., Liebman, H.A., Forssen, E., Ross, M.E., Levine, A.M. (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. Journal of Clinical Oncology, 13, 996 1003.
  • 29
    Goorin, A.M., Chauvenet, A.R., Perez-Atayde, A.R., Cruz, J., McKane, R., Lipshultz, S.E. (1990) Initial congestive heart six to ten years after doxorubicin chemotherapy for childhood cancer. Journal of Pediatrics, 116, 144 147.
  • 30
    Gordon, K.B., Tajuddin, A., Guitart, J., Kuzel, T.M., Eramo, L.R., Von Roenn, J. (1995) Hand–foot syndrome associated with liposomal-encapsulated doxorubicin therapy. Cancer, 75, 2169 2173.
  • 31
    Hancock, S.L., Tucker, M.A., Hoppe, R.T. (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. Journal of the American Medical Association, 270, 1949 1955.
  • 32
    Harrison, M., Tomlinson, D., Stewart, S. (1995) Liposomal entrapped doxorubicin: an active agent in AIDS related Kaposi's sarcoma. Journal of Clinical Oncology, 13, 914 920.
  • 33
    Hasinoff, B.B., Hellman, K., Herman, E.H., Ferrans, V.J. (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Current Medicinal Chemistry, 5, 1 28.
  • 34
    Herman, E.H. & Ferrans, V.J. (1981) Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with ICRF-187. Cancer Research, 41, 3436 3440.
  • 35
    Herman, E.H. & Ferrans, V.J. (1983) Influence of vitamin E and ICRF-187 on chronic cardiotoxicity in miniature swine. Laboratory Investigation, 46, 69 77.
  • 36
    Herman, E.H., Mahre, R.M., Lee, I.P., Waravdekar, V.S. (1972) Prevention of the cardiotoxic effects of adriamyctin and daunomycin in the isolated dog heart. Proceedings of the Society for Experimental Biology and Medicine, 140, 234 239.
  • 37
    Hershko, C., Pinson, A., Link, G. (1996) Prevention of anthracycline cardiotoxicity by iron chelation. Acta Haematologica, 95, 87 92.
  • 38
    Hitchcock-Bryans, S., Gelber, R., Cassady, J.R., Sallan, S.E. (1986) The impact of induction anthracycline on long term failure free survival in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology, 14, 211 215.
  • 39
    Hochster, H., Wasserheit, C., Speyer, J. (1995) Cardiotoxicity and cardioprotection during chemotherapy. Current Opinions in Oncology, 7, 304 309.
  • 40
    Holmberg, S.R.M. & Williams, A.J. (1990) Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sacroplasmic reticulum. Circulation Research, 67, 272 283.
  • 41
    Hortobagyi, G.N., Frye, D., Buzdar, A.U. (1989) Decreased cardiac toxicity of doxorubicin administration by continuous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer, 63, 37 45.
  • 42
    Hu, X.F., Slater, A., Wall, D.M., Kantharidis, P., Parkin, J.D., Cowman, A., Zaleberg, J.R. (1995) Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line . British Journal of Cancer, 71, 931 936.
  • 43
    Iarussi, D., Auricchiot, U., Agretto, A., Murano, A., Guiuliano, M., Casale, F., Indolfi, P., Iacono, A. (1994) Protective effect of coenzyme Q10 on anthracyclines cardiotoxicty: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Molecular Aspects of Medicine, 15, S207 S212.
  • 44
    Ito, H., Miller, S.C., Billihngham, M.E., Akimoto, H., Torti, S.V., Wade, R., Gahlman, R., Lyons, G., Kedes, L., Torti, F.M. (1990) Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and vitro. Proceedings of the National Academy of Sciences of the United States of America, 87, 4275 4279.
  • 45
    Jain, K.K., Casper, E.S., Gellar, N.L., Hakes, T.B., Kaufman, R.J., Currie, V., Schwartz, W., Cassidy, C., Petroni, G.R., Young, C.W., Wittes, R.E. (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. Journal of Clinical Oncology, 3, 818 826.
  • 46
    Johnson, S.A. & Richardson, D.S. (1998) Anthracyclines in haematology: pharmacokinetics and clinical studies. Blood Reviews, 12, 52 71.
  • 47
    Kakadekar, A.P., Sandor, G.G.S., Fryer, C., Chan, K.W., Rogers, P.C., Pritchard, S., Popov, R. (1997) Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients. Medical and Pediatric Oncology, 28, 22 26.
  • 48
    Kusuoka, H., Futaki, S., Koretsune, Y., Kitabatake, A., Suga, H., Kumada, T., Inoue, M. (1991) Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. Journal of Cardiovascular Pharmacology, 18, 437 44.
  • 49
    Krischer, J.P., Cuthbertson, D.D., Epstei, S., Gorin, A.M., Epstein, M.L., Lipshultz, S.E. (1998) Risk factors for early anthracycline clinical cardiotoxicity in children: the pediatric oncology group experience. Progress in Pediatric Cardiology, 8, 83 90.
  • 50
    Lefrack, E.A., Pitha, L., Rosenheim, S., Gottlieb, J.A. (1973) A clinicopathologixcal analysis of anthracycline antibiotic cardiotoxicity. Cancer, 32, 304 314.
  • 51
    Legha, S.S., Benjamin, R.S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S.L., Blumenschein, G.R., Freireich, E.J. (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Annals of Internal Medicine, 96, 133 139.
  • 52
    Levitt, G., Bunch, K., Rogers, C.A., Whitehead, B. (1996) Cardiac transplantation in childhood cancer survivors in Great Britain. European Journal of Cancer, 32A, 826 830.
  • 53
    Lopez, M., Vici, P., Di Lauro, L., Conti, F., Paoletti, G., Ferraironi, A., Sciuto, R., Giannarelli, D., Maini, C.L. (1998) Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. Journal of Clinical Oncology, 16, 86 92.
  • 54
    Lilleyman, J.S., Gibson, B.E.S., Stevens, R.F., Will, A.M., Hann, I.M., Richards, S.M., Hill, F.G.H. (1997) Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. British Journal of Haematology, 97, 603 606.
  • 55
    Lipshultz, S.E. (1996) Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. Journal of Clinical Oncology, 14, 328 330.
  • 56
    Lipshultz, S.E., Colan, S.D., Gelber, R.D., Perez Atayde, A.R., Sallan, S.E., Sanders, S.P. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in children. New England Journal of Medicine, 324, 808 815.
  • 57
    Lipshultz, S.E., Lipsitz, S.R., Mone, S.M., Goorin, A.M., Sallen, S.E., Sanders, S.P., Orav, E.J., Gelber, R.D., Colan, S.D. (1995) Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. New England Journal of Medicine, 332, 1738 1743.
  • 58
    McBride, N.C., Richardson, D.S., Johnson, S., Schey, S., Gray, A., Newland, A.C., Kelsey, S.M. (1997) Liposomal daunorubicin (DaunoXome) as a single agent and in combination therapy for poor prognosis lymphoma. British Journal of Haematology, 97, (Suppl 1), 25.
  • 59
    Milei, J., Boveris, A., Llesuv, S., Mulina, H.A., Storino, R., Ortega, D., Mile, S.E. (1986) Amelioration of adriamycin-induced cardiotoxicity of vitamin A and E. American Heart Journal, 111, 95 102.
  • 60
    Muller, C., Chatelut, E., Gualano, V., De Forni, M., Huguet, F., Attal, M., Canal, P., Laurent, G. (1993) Cellular pharmokinetics of doxorubicin in patients with chronic lymphatic leukaemia: comparison of bolus administration and continuous infusion. Cancer Chemotherapeutics and Pharmacology, 3, 379 384.
  • 61
    Myers, C., Bonow, R., Palmeri, S., Jenkins, J., Corden, B., Locker, G., Doroshow, J., Epstein, S. (1983) A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Seminars in Oncology, 10, 53 55.
  • 62
    Neglia, J.P. & Woods, W.G. (1986) Continuous infusion doxorubicin in the treatment of primary hepatic malignancies of childhood. Cancer Treatment Reports, 70, 655 657.
  • 63
    Northfelt, D.W., Dezube, B.J., Thommes, J.A., Miller, B.J., Fischl, M.A., Friedman-Klien, A., Kaplan, L.D., Du Mond, C., Mamelok, R.D., Henry, D.H. (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. Journal of Clinical Oncology, 16, 2445 2451.
  • 64
    Nysom, K., Colan, S.D., Lipshultz, S.E. (1998) Late cardiotoxicity following anthracycline therapy for childhood cancer. Progress in Pediatric Cardiology, 8, 121 138.
  • 65
    Painter, R.B. (1978) Inhibition of DNA replication initiation by 4-nitroquinoline 1-oxide adriamycin and ethyleneimine. Cancer Research, 38, 4445 4449.
  • 66
    Patel, K.R., Tin, G.W., Williams, L.E., Baldeschwieler, J.D. (1985) Biodistribution of phospholipid vesicles in mice bearing Lewis lung carcinoma and granuloma. Journal of Nuclear Medicine, 26, 1048 1055.
  • 67
    Preisler, H.D., Gessner, T., Azarnia, N., Bolanowska, W., Epstein, J., Early, A.P., D'Arrigo, P., Vogler, R., Winton, L., Chervenik, P., Joyce, R., Lee, H., Steele, R., Goldberg, J., Gottlieb, A., Browman, G., Miller, K., Grunwald, H., Larson, R., Brennan, J. (1984) Relationship between plasma levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemotherapeutics and Pharmocology, 12, 125 130.
  • 68
    Presant, C.A., Blayney, D., Proffitt, R.T., Turner, A.F., Williams, L.E., Nadel, H, I., Kennedy, P., Wiseman, C. (1990) Preliminary report; imaging of Kaposi's sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet, 335, 1307 1309.
  • 69
    Presant, C.A., Proffitt, R.T., Turner, A.F., Williams, L.E., Winsor, D., Werner, J.L., Kennedy, P., Wiseman, C., Gala, Kirit., McKenna, R.J., Smith, J.D., Bouzaglou, S.A., Callahan, R.A., Baldeschwieler, J., Crossley, R.J. (1988) Successful imaging of human cancer with indium-111-labelled phospholipid vesicles. Cancer, 62, 905 911.
  • 70
    Roberts, J. (1987) Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration? Cancer Drug Delivery, 4, 191 199.
  • 71
    Ryberg, M., Nielson, D., Skovsgaard, T., Hansen, J., Jensen, B.V., Dombernowsky, P. (1998) Epirubicin cardiotoxicity: an analysis of 469 patients with metastic breast cancer. Journal of Clinical Oncology, 16, 3502 3508.
  • 72
    Samuels, L., Cummings, J., Shaw, P. (1998) Daunorubicin cardiotoxicity in childhood cancer. Lancet, 352, 1150.
  • 73
    Schiavetti, A., Castello, M.A., Versacci, P., Varrasso, G., Padula, A., Ventriglia, F., Werner, B., Colloridi, V. (1997) Use of IRCF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatric Haematology and Oncology, 14, 213 222.
  • 74
    Shan, K., Lincoff, A.M., Young, J.B. (1996) Anthracycline-induced cardiotoxicity. Annals of Internal Medicine, 125, 47 58.
  • 75
    Shapiro, J., Gotfried, M., Lishner, M., Ravid, M. (1990) Reduced cardiotoxicity of doxorubicin by a 6-hour infusion: a prospective randomized evaluation. Cancer, 65, 870 873.
  • 76
    Singal, P.K., Siveski-Iliskovic, N., Hill, M., Thomas, T.P., Timao, L. (1995) Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. Journal of Clinical Cell Cardiology, 27, 1055 1062.
  • 77
    Smith, M.A., Ungerleider, R.S., Hurwitz, M.E., Simon, R. (1991) Influence of doxorubicin dose intensity on response and outcome for patients with oesteogenic sarcoma and Ewing's sarcoma. Journal of the National Cancer Institute, 83, 1460 1470.
  • 78
    Sorenson, K., Levitt, G., Sebag-Montefiore, D., Bull, C., Sullivan, I. (1995) Cardiac function in Wilms tumor survivors. Journal of Clinical Oncology, 13, 1546 1556.
  • 79
    Speth, P.A.J., Linssen, P.C., Boezeman, J.B.N., Wessels, H.M.C., Haanen, C. (1987) Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemotherapy and Pharmacology, 20, 305 310.
  • 80
    Speyer, J.L., Green, M.D., Zeleniuch-Jacquotte, A., Wernz, J.C., Rey, M., Sanger, J., Kramer, E., Ferrans, V., Hochster, H., Myers, M., Blum, R.H., Feit, F., Attubato, M., Burrows, W., Muggia, F.M. (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. Journal of Clinical Oncology, 10, 117 127.
  • 81
    Steinhertz, L.J., Steinhertz, P.G., Tan, T.C., Heller, G., Murphy, L. (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Journal of the American Medical Association, 266, 1672 1677.
  • 82
    Steinhertz, P.G., Ridner, A., Steinhertz, L.J., Meyers, P., Tan, C., Heller, G., (1993) Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-11. Cancer, 72, 3120 3130.
  • 83
    Swain, S.M., Whaley, F.S., Gerber, M.C., Weisberg, S., York, M., Spicer, D., Jones, S.E., Wadler, S., Desai, A., Vogel, C., Speyer, J., Mittelman, A., Reddy, S., Pendergrass, K., Valez-Garcia, E., Ewer, M.S., Branchine, J.R., Gams, R.A. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology, 15, 1318 1332.
  • 84
    Tanabe, K., Ikegami, Y., Lishida, R., Andoh, T. (1991) Inhibition of topoisomerase II by antitumour agents bis(2,6-dioxopiperazine) derivatives. Cancer Research, 51, 4903 4908.
  • 85
    Torti, F.M., Bristow, M.R., Howes, A.E., Aston, D., Stockdale, F.E., Carter, S.K., Kohler, M., Brown, B.W., Billingham, M.E. (1983) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Annals of Internal Medicine, 99, 745 749.
  • 86
    Truesdell, S., Schwartz, C.L., Clark, E., Constine, L.S. (1994) Cardiovascular effects of cancer. In: Survivors of Childhood Cancer (ed. by C. L. Schwartz, W. L. Hobbie, L. S. Constine and K. S. Ruccione). Mosby, St Louis.
  • 87
    Tulpule, A., Yung, R.C., Espina, B.M., Scadden, D.T., Cabriales, S., Ilaw, M., Boswell, W., Gill, P.S. (1998) Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. Journal of Clinical Oncology, 16, 3369 3374.
  • 88
    Twelves, C.J., Dobbs, N.A., Aldhous, M., Harper, P.G., Rubens, R.D., Richards, M.A. (1991) Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemotherapy and Pharmacology, 28, 302 307.
  • 89
    Umsawasdi, T., Valdivieso, M., Booser, D.J., Barkley, H.T., Ewer, M., MacKay, B., Dhingra, H.M., Murphy, W.K., Spitzer, G., Chiuten, D.F., Dixon, C., Farha, P., Carr, D.T. (1989) Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, cisplatin chemotherapy for non-small cell lung cancer. Cancer, 64, 1995 2000.
  • 90
    Usui, N., Dobashi, N., Kobayashi, T., Yano, S., Maki, N., Asai, O., Saito, T., Yamaguchi, Y., Watanabe, H., Kato, A., Ogihara, A., Katori, M., Nagamine, M., Takei, Y., Yamazak, H., Funakoshi, S., Tajima, N., Ogawa, M., Kuraishi, Y. (1998) Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. Journal of Clinical Oncology, 16, 2086 2092.
  • 91
    Uziely, B., Jeffers, S., Isacson, R., Kimberlea, K., Wei-Tsao, D., Yehoshua, Z., Libcon, E., Muggia, F.M., Gabizon, A. (1995) Liposomal doxorubicin: antitumour activity and unique toxicities during two complementary phase I studies. Journal of Clinical Oncology, 13, 1777 1785.
  • 92
    Vaage, J., Uster, P.S., Working, P.K. (1998) Therapy of human carcinoma xenografts with doxorubicin encapsulated insterically stabilized liposomes (DOXIL): efficacy and safety studies. Long Circulating Liposomes: Old drugs, New Therapeutics (ed. by M. C. Woodle and G. Storm), pp. 60 72. Springer-Verlag and Landes Bioscience.
  • 93
    Valdivieso, M., Burgess, M.A., Ewer, M.S., Mackay, B., Wallace, S., Benjamin, R.S., Ali, M.K., Bodey, G.P., Freireich, E.J. (1984) Increased therapeutic index or weekly doxorubicin in the therapy of non small round cell lung cancer: a prospective, randomized study. Journal of Clinical Oncology, 2, 207 214.
  • 94
    Venturni, M., Michelatti, A., Del Mastro, L., Gallo, L., Carino, F., Garrone, O., Tibaldi, C., Molea, N., Bellina, R.C., Pronzato, P., Cyrus, P., Vinke, J., Testore, F., Guelfi, M., Lionetto, R., Bruzzi, P., Conte, P.F., Rosso, R. (1996) Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in woman receiving epirubicin chemotherapy for advanced breast cancer. Journal of Clinical Oncology, 14, 3112 3120.
  • 95
    Von Hoff, D.D., Layard, M., Basa, P., Davis, H.L., Von Hoff, A.L., Rozeneweig, M., Muggia, F.M. (1979) Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710 717.
  • 96
    Von Hoff, D.D., Rozeneweig, M., Layard, M., Slavik, M., Muggia, F.M. (1977) Daunomycin induced cardiotoxicity in children and adults. American Journal of Medicine, 62, 200 208.
  • 97
    Wexler, L.H., Andrich, M.P., Venzon, D., Berg, S.L., Weaver-McClure, L., Chen, C.C., Dilsiizian, V., Avila, N., Jaroninski, P., Balis, F.M., Poplack, D.G., Horowitz, M.E. (1996) Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. Journal of Clinical Oncology, 14, 362 372.
  • 98
    Wickman-Coffelt, J., Rapcsak, M., Sievers, R., Rouleau, J.L., Parmley, W.W. (1983) Verapamil, propranolol, and hydralazine protect against the acute cardiac depression induced by adriamycin. Cardiovascular Research, 17, 43 49.
  • 99
    Wu, N.Z., Da, D., Rudoll, T.L., Needham, D., Whorton, A.R., Dewhurst, M.W. (1993) Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Research, 53, 3765 3770.
  • 100
    Zalupski, M., Metch, B., Balcerzak, S., Fletcher, W.S., Chapman, R., Bonnet, J.D., Weiss, G.R., Ryan, J., Benjamin, R.S., Baker, L.H. (1991) Phase III comparison of doxorubicin given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. Journal of the National Cancer Institute, 83, 926 932.